The JUPITER study, published in The New England Journal of Medicine, analyzes treatment with rosuvastatin as a prevention when it comes to cardiovascular risks.
This drug is used to control the synthesis of cholesterol, which reduces its intracellular deposits and, therefore, its presence.
The study was carried out based on 17,802 healthy men and women, with high sensitivity of the C-reactive protein, but without hyperlipidemias, ie level of normalized blood lipids.
What is C-Reactive Protein (PCR)
The C Reactive Protein (CRP) is produced by the liver rising its level when there is inflammation in the body. The doctor uses this test to check inflammatory diseases or to check that the anti-inflammatory drug is working.
A more sensitive PCR test, called a high sensitivity PCR assay, determines the risk of heart disease in a person. Many experts believe that a high CRP level is a positive factor for heart disease. According to the American Heart Association, people at low risk of developing cardiovascular disease have high sensitivity CRP levels below 1.0 mg / L. Those at high risk, above 3 mg / L.
In another study of men over 50 and women over 60, one group received 20 mg of rosuvastatin a day, for almost two years, compared to another group given placebo. Laboratory follow-ups, medications, structured interviews and evaluation of the results and possible adverse effects were evaluated.
This research concludes that, in apparently healthy men and women who did not have hyperlipidemia, but high levels of C-reactive protein, the rates of a first cardiovascular event and death from any cause among those who received rosuvastatin were significantly reduced, compared with those who received placebo.